Abstract | BACKGROUND: METHODS: RESULTS:
L-NAME-treated SHR developed massive proteinuria, severe hypertensive nephrosclerosis, and tubulointerstitial damage. Eplerenone significantly reduced proteinuria (127.4 +/- 26.5 vs. 51.9 +/- 16.7 mg/24 h, p < 0.01), improved glomerular and arteriolar injuries (65 +/- 9 vs. 29 +/- 9 score/100 glomeruli, p < 0.01; 116 +/- 18 vs. 41 +/- 13 score/100 arterioles, p < 0.01, respectively), and decreased tubulointerstitial damage index (1.43 +/- 0.07 vs. 0.39 +/- 0.07, p < 0.01) without altering mean arterial pressure or glomerular dynamics. Combined therapy of eplerenone with lisinopril produced no further benefits than lisinopril alone. CONCLUSION:
|
Authors | Xiaoyan Zhou, Hidehiko Ono, Yuko Ono, Edward D Frohlich |
Journal | American journal of nephrology
(Am J Nephrol)
2004 Mar-Apr
Vol. 24
Issue 2
Pg. 242-9
ISSN: 0250-8095 [Print] Switzerland |
PMID | 15031627
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2004 S. Karger AG, Basel |
Chemical References |
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Eplerenone
- NG-Nitroarginine Methyl Ester
|
Topics |
- Animals
- Eplerenone
- Hemodynamics
(drug effects)
- Kidney Glomerulus
(drug effects, pathology, physiopathology)
- Male
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- NG-Nitroarginine Methyl Ester
(pharmacology)
- Nephrosclerosis
(drug therapy, pathology)
- Proteinuria
(drug therapy)
- Rats
- Rats, Inbred SHR
- Spironolactone
(analogs & derivatives, therapeutic use)
|